Spyre Therapeutics, Inc. (SYRE)
33.80
-0.56
(-1.63%)
USD |
NASDAQ |
Dec 12, 13:45
Spyre Therapeutics Research and Development Expense (Quarterly): 45.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| PTC Therapeutics, Inc. | 100.16M |
| NovaBay Pharmaceuticals, Inc. | -- |
| Palatin Technologies, Inc. | 2.526M |
| Theriva Biologics, Inc. | 2.551M |
| Oragenics, Inc. | 0.9309M |